88,800 The Chemours Company $CC Shares Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in The Chemours Company (NYSE:CC) by 853.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 99,200 shares of the specialty chemicals company’s stock after purchasing an additional 88,800 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.07% of Chemours worth $1,346,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. purchased a new position in Chemours during the 2nd quarter worth $34,000. Allworth Financial LP purchased a new stake in shares of Chemours in the 2nd quarter worth $51,000. State of Wyoming purchased a new stake in shares of Chemours in the 2nd quarter worth $67,000. Sterling Capital Management LLC lifted its holdings in shares of Chemours by 839.3% in the 3rd quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock worth $69,000 after buying an additional 4,532 shares during the period. Finally, Nykredit A S bought a new position in shares of Chemours during the 2nd quarter worth $99,000. Hedge funds and other institutional investors own 76.26% of the company’s stock.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched FaizEon two-phase liquid-cooling solutions for AI data centers, positioning the company to pursue demand from a fast-growing market. Article: Chemours launches FaizEon liquid-cooling solutions
• Positive Sentiment: Fourth-quarter 2026 revenue guidance of $1.7 billion–$1.8 billion is above the cited $1.4 billion consensus, offering a more favorable near-term sales outlook. Full-year revenue guidance of $5.9 billion was in line with consensus.
• Positive Sentiment: Truist maintained a Buy rating, though it lowered its price target to $18 from $20. Article: Truist price-target update
• Neutral Sentiment: UBS kept its Neutral rating but cut its target to $15 from $16, signaling limited conviction despite a target above the cited share price. Article: UBS adjusts Chemours price target
• Negative Sentiment: Third-quarter adjusted EPS of $0.21 missed the $0.26 consensus. Analyst commentary also cited weak volumes and a cautious fourth-quarter outlook, tempering the stronger revenue guidance. Article: Q3 results and outlook
• Negative Sentiment: Multiple law firms publicized a securities class action alleging Chemours misled investors about Opteon refrigerant aftermarket demand and distributor inventory. The claims are allegations, but the litigation may add uncertainty; the lead-plaintiff deadline is December 7, 2026. Article: Chemours class-action notice

Chemours Trading Up 5.1%

Shares of NYSE CC opened at $13.76 on Thursday. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.88. The stock has a market capitalization of $2.07 billion, a P/E ratio of -13.49 and a beta of 1.47. The Chemours Company has a 1-year low of $10.44 and a 1-year high of $28.67. The business has a fifty day moving average price of $14.08 and a 200 day moving average price of $18.25.

Chemours (NYSE:CC) last issued its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the previous year, the business earned $0.40 EPS. Chemours’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities research analysts expect that The Chemours Company will post 0.83 EPS for the current fiscal year.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, November 16th. Chemours’s dividend payout ratio (DPR) is currently -34.31%.

Insider Transactions at Chemours

In other news, CEO Denise Dignam acquired 3,378 shares of Chemours stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the purchase, the chief executive officer directly owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, with a total value of $30,050.55. Following the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on CC shares. The Goldman Sachs Group restated a “neutral” rating and set a $16.00 price target on shares of Chemours in a research note on Friday, October 9th. BMO Capital Markets lowered their price objective on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a report on Thursday, September 10th. Truist Financial cut their target price on shares of Chemours from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, UBS Group cut their target price on shares of Chemours from $16.00 to $15.00 and set a “neutral” rating on the stock in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.45.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.